by week 10 (Figure 3A). Interestingly, AD patients of color (Fitz IV-VI, n=31) showed earlier reduction in itching sensation with cleanser at week 2, despite experiencing greater sensation at baseline compared to white counterparts (Fitz I-III, n=38) (Figure 3B). These results were consistent with the significant improvement in quality-of-life perceived by all AD subjects (Figure 4A & 4B). Xerosis subjects perceived significant increase in itching sensation with cleanser alone at 2 weeks, reaching complete relief with regimen by week 8 (Figure 3A). Despite experiencing this initial increase in itch sensation, xerosis patients perceived a significant reduction in itching intensity levels with cleanser alone at week 2, and with regimen by week 10 (Figure 3C). Interestingly, xerosis patients of color (Fitz IV-VI, n=25) showed earlier reduction in itching intensity (Figure 3D), while white counterparts (Fitz I-III, n=44) showed greater improvement in quality-of-life with cleanser alone and with regimen overtime (Figure 4A & 4C).
